According to Future Market Insights, the heparin-induced thrombocytopenia (HIT) treatment market is likely to be valued at US$ 9.8 billion in 2023. The scope of the market is further expected to grow, registering a value CAGR of 5% throughout the 2023 to 2033 forecast period. By the end of the said period of assessment, a valuation of US$ 15.97 billion is anticipated.
Heparin-induced thrombocytopenia (HIT) is a leading cause of morbidity and mortality in hospitalized patients, occurring as an after-effect of life and limb-threatening thrombosis. This condition is prevalent in at least 5% of patients who are exposed to heparin. Characteristics signs include a drop in platelet count of over 50% and the formation of additional blood clots. Hence, it is becoming highly important to treat this condition, paving way for a host of treatment approaches.
Currently, there are a handful of drugs that are deployed to treat heparin-induced thrombocytopenia, such as argatroban and lepirudin. Both drugs are directly injected into the patient’s vein, and help inhibit clotting. Other drugs which have been used to treat minor HIT cases include bivalirudin and fondaparinux. These two drug candidates are still being studied for use in more complicated forms of HIT. Once complete, these are expected to prove highly effective as oral medications in the future.
Over the years, the prevalence of chronic heart ailments and cardiac anomalies has compounded significantly. From 1990 to 2019, the incidence of cardiovascular disease grew nearly twofold, from 271 million to 523 million. From aortic disease to arrhythmia, congenital heart disease to deep vein thrombosis, cases have risen alarmingly. Hence, surgical intervention has become a necessity. Post-surgery, patients are generally administered heparin to prevent blood clotting.
In terms of diagnosis, a number of laboratory tests, including enzyme-linked immunoassay (ELISA), enzyme immunoassay (EA), serotonin release assay (SRA), and heparin-induced platelet activation (HIPA), are prevalent. Out of all the above-mentioned tests, serotonin release assay (SRA) tests are expected to be heavily relied upon. SRA-based tests offer higher sensitivity and specificity, making it easier to detect any possible symptoms of HIT. Accuracy rates are as high as 95%. Furthermore, the test is highly effective for detecting highly pathogenic HIT sera, comprising heparin-dependent and heparin-independent platelet-activating antibodies.
The United States is forecast to be a hotbed for heparin-induced thrombocytopenia testing, diagnosis, and treatment in the forthcoming decade. Nearly 12 million individuals, or 33% of all hospitalized patients, are administered some quantities of heparin annually across the country. Studies reveal that 0.76% of patients receiving therapeutic doses of intravenous unfractionated heparin (UFH) develop HIT. Mortality arising out of the condition is as high as 20%. As a result, healthcare providers are scrambling to invest in therapeutic and treatment areas.
Companies in the HIT treatment landscape are vying to expand their profitability by deploying a wide array of expansion strategies. These primarily involve the introduction of novel therapies and the introduction of prescribed drug candidates. Pfizer Inc., for instance, offers its own range of argatroban injections for prophylaxis or treatment of thrombosis in adult patients diagnosed with HIT. In addition, the company also manufactures bivalirudin for use as an anticoagulant in patients undergoing percutaneous coronary intervention, including HIT patients. The recommended dosage for the drug is a 0.75 mg/kg intravenous bolus, followed immediately by a 1.75 mg/kg/h intravenous infusion.
| Data Points | Key Statistics |
|---|---|
| Anticipated Market Value for Heparin-Induced Thrombocytopenia (HIT) Treatment in 2023 | US$ 9.8 billion |
| Projected Market Value for Heparin-Induced Thrombocytopenia (HIT) Treatment in 2033 | US$ 15.97 billion |
| Global Growth Rate (2023 to 2033) | CAGR of 5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Heparin-Induced Thrombocytopenia (HIT) is an immune-mediated life-threatening complication. It is an adverse drug reaction caused by the generation of antibodies that activates platelet factor 4(PF-4) in the presence of heparin.
Heparin-Induced Thrombocytopenia (HIT) can lead to many thromboembolic complications, such as acute myocardial infarction, pulmonary embolism, deep venous thrombosis, thrombotic stroke and pulmonary embolism.
A number of laboratory tests like Enzyme-Linked Immunosorbent Assay (ELISA), Serotonin Release Assay (SRA), Enzyme Immunoassay (EIA), Heparin-Induced Platelet Activation (HIPA) Tests are now available to confirm the diagnosis of Heparin-induced thrombocytopenia (HIT) treatment. Heparin-Induced Thrombocytopenia (HIT) treatment can be mediated by three alternative anticoagulants. These include Lepirudin, Danaparoid and Argatroban.
These antithrombotic drugs are immediately active and are direct inhibitors of thrombin. They also inhibit thrombin generation and are routinely monitored. These drugs are monitored with ecarin the clotting time (ECT) for lepirudin, the activated clotting time (ACT) for argatroban, or anti?Xa assays for danaparoid.
However, consideration should be given towards the safety and efficacy of the alternative anticoagulant drug for the heparin-induced thrombocytopenia (HIT) treatment. The patient's clinical status including renal and hepatic function, likely risks and benefits should be monitored during the heparin-induced thrombocytopenia (HIT) treatment.
Increase administration of various forms of heparin, an anticoagulant for the treatment of cardiovascular and orthopaedic surgery and invasive procedures increase the chances of heparin-induced thrombocytopenia, which drives the heparin-induced thrombocytopenia (HIT) market.
Heparin is widely being used in acute coronary syndromes, atrial fibrillation, venous thromboembolism, dialysis, peripheral occlusive disease, and during extracorporeal circulation which increase the chances of heparin-induced thrombocytopenia (HIT) and drives the market of heparin-induced thrombocytopenia (HIT) treatment.
About 12 million hospitalized patients in the USA, around one third in a year, are receiving heparin, which is expected to drive the heparin-induced thrombocytopenia (HIT) treatment market. However, due to the various complications of heparin-induced thrombocytopenia (HIT) treatment and side effects of the available drugs expected to restraints the heparin-induced thrombocytopenia (HIT) treatment market.
Principal Consultant
The growth of heparin-induced thrombocytopenia (HIT) treatment market is expected to be high during forecasting periods due to the life-threatening complication of the disease. Increasing administration of heparin develops the possibilities of life-threatening heparin-induced thrombocytopenia (HIT), which will drive the heparin-induced thrombocytopenia (HIT) treatment market.
However, due to the less availability of sophisticated drugs and therapies, there is a huge opportunity among the key market players for the development of novel drug and therapies for the heparin-induced thrombocytopenia (HIT) treatment during the near forecasting periods
USA is expected as the largest regional market share in the heparin-induced thrombocytopenia (HIT) treatment market owing to high patient awareness levels, the presence of more number of market players, increasing awareness about heparin-induced thrombocytopenia (HIT) treatment and marketing activities in the region followed by Europe.
The heparin-induced thrombocytopenia (HIT) treatment market is expected to grow fastest in the Asia Pacific may because of the increasing prevalence of cardiovascular and acute coronary syndromes, thus boosting the market growth.
However, in the South Asian countries such as India and China, the opportunities to manufacture and distribute new heparin-induced thrombocytopenia (HIT) treatment drugs is expected to be higher due to large population and increasing incidence of heparin-induced thrombocytopenia during forecasting periods.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key players of heparin-induced thrombocytopenia (HIT) treatment market includes Pfizer Inc., Alleviare Life Sciences Pvt. Ltd., ANDOZ, GlaxoSmithKline Plc., Eagle Pharmaceuticals Inc. Teva Pharmaceutical Industries Ltd., WEST-WARD, INC among others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Explore Healthcare Insights
View Reports
Heparin-Induced Thrombocytopenia (HIT) Treatment Market
